Bristol myers squibb dasatinib patent 2000?

Do you want specific patent numbers and expiration dates for dasatinib (Sprycel) by Bristol Myers Squibb, or a general overview of the patent landscape around 2000?

Here’s some context you can use right away:
- Dasatinib is a BMS-developed tyrosine kinase inhibitor (BCR-ABL/SRC family). The patent coverage for dasatinib is not a single “2000 patent” but a family of patent applications filed in the late 1990s and published in the early 2000s.
- The core patent families cover the compound itself and its use in cancer treatment, plus later patents cover formulations, methods of synthesis, and specific therapeutic uses.
- Because there are multiple jurisdictions (US, Europe, Asia, etc.) and multiple families, the exact numbers, scope, and expiry dates vary by country and by term changes.

If you want precise details, tell me:
- Which jurisdiction(s) you care about (e.g., US, EU, UK, JP, etc.)
- Whether you want (a) composition-of-matter patents (the compound itself), (b) method-of-use patents (treating cancer with dasatinib), or (c) formulation/specific-use patents
- Whether you want current status and expiry dates, or just the original filing/publication numbers

I can guide you to the relevant patent families and how to check their status (e.g., via Google Patents or the USPTO/EUIPO databases). Also note: for legal or freedom-to-operate (FTO) questions, it’s best to consult a patent attorney.